Veterans with bipolar disorders (BD) experience recurrent and seemingly unpredictable periods of severe impairments in psychosocial functioning, such as participation in social roles and activities. Many effective treatments for BD emphasize early detection of bipolar episodes, in order to make necessary treatment adjustments and prevent psychosocial impairments associated with acute mood episodes. Unfortunately, acute mood episodes in BD are also associated with a decrease in a patient's insight into their own symptoms, which can prevent one's ability to self-report first signs of symptoms and functional declines. Moreover, routine care visits for BD are typically too infrequent to capture and effectively monitor day-to-day changes in a patient's mood and functioning.
Objective, low-effort, and continuous methods of tracking symptoms and social participation of Veterans with BD in real-time and in-situ are needed to provide early (i.e., days in advance) warning signs of acute bipolar episodes and functional declines, which in turn would enable well-timed interventions to prevent poor psychosocial outcomes. mHealth refers to the use of mobile and wireless devices as part of patient care and offers many potential opportunities for early detection of and intervention for acute mood states in this population. However, these mHealth approaches have not been investigated in Veterans with BD. In a Small Projects in Rehabilitation Research (SPiRE)-funded pilot study, the investigator team established high feasibility and acceptability of one such innovative passive mHealth approach using a smartphone program, or an app, in a small sample of Veterans with BD to track their smartphone's GPS/location. The pilot study used a priori location context ratings of visited places (e.g., a priori ratings on types of activities usually engaged in at a frequently visited location) to derive unobtrusive measures of social participation (e.g., time spent at work-related locations). The goal of this Merit Review proposal is to establish reliable and valid machine-learning algorithms using the same types of mHealth data to prospectively (days in advance) detect declines in social participation and prospective onset of mania and depression in Veterans with BD. This proposal has three aims:
Aim 1. To establish a machine learning algorithm using GPS/location data for predicting prospective declines in social participation in Veterans with BD.
Aim 2. To establish machine learning algorithms using GPS/location data for predicting prospective acute BD clinical states. The investigators will explore whether adding more burdensome daily self-report and voice diaries' speech analysis features improves the models' precision using statistical indices of prediction precision or accuracy.
Aim 3. To explore clinical implementation of the mHealth-based algorithms in treatment of BD. Focus groups of VA providers and administrators will assess feasibility of algorithms' implementation in clinical care.

开始日期2024-07-01

申办/合作机构

VA Office of Research and Development

[+2]

NCT05891639 / Not yet recruitingN/A

Investigating Factors Affecting Clinical Trial Participation Rates in Patients With Bipolar Disorder

Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups.
This study will investigate the safety and efficacy of bipolar disorder treatments. The focus will be on tracking the rates of completion and withdrawal among these individuals.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future bipolar disorder study.

开始日期2024-06-01

申办/合作机构

Power Life Sciences, Inc.初创企业

ISRCTN43081021 / RecruitingN/AIIT

Barriers and facilitators to accessing sexual health care for people with severe mental illness in England

开始日期2024-05-01

申办/合作机构

King's College London

100 项与躁郁症相关的临床结果

登录后查看更多信息

100 项与躁郁症相关的转化医学

登录后查看更多信息

0 项与躁郁症相关的专利（医药）

登录后查看更多信息

42,400

项与躁郁症相关的文献（医药）

2024-12-30·Acta neurologica Taiwanica

Taste Disorder and Tongue Numbness After Lithium Overdose.

Article

作者: Si-Yu Chu ; Huang-Chi Wang ; Ming-Hong Hsieh ; Cheng-Chen Chang

PURPOSE:

Drug-induced taste disturbances are prevalent in clinical practice, with dysgeusia being a frequent manifestation. This study aims to present a case of taste disorders and tongue numbness induced by a lithium overdose.

CASE REPORT:

A 33-year-old woman with bipolar II disorder attempted suicide by ingesting multiple drugs, including lithium and benzodiazepines. She exhibited weakness but was conscious after admission. Laboratory analyses indicated elevated serum lithium and urine benzodiazepine levels. Admitted to a psychiatric ward, her symptoms included diarrhea, poor appetite, and postprandial nausea. Two weeks later, she reported altered taste sensations and tongue numbness following the overdose. Her ongoing medication included venlafaxine, valproate sodium, and clozapine. Symptoms improved over time without specific treatment, aligning with increased appetite and weight gain.

CONCLUSION:

Drug-induced taste disturbances have a substantial impact on patients' quality of life and medication adherence. This case brings attention to taste disorders induced by lithium and suggests potential mechanisms that could contribute to taste alterations. It underscores the importance of conducting thorough assessments in patients experiencing gustatory symptoms, particularly during the ongoing pandemic.

2024-07-01·Neural regeneration research

Lactate: a prospective target for therapeutic intervention in psychiatric disease.

Article

作者: Yanhui Cai ; Haiyun Guo ; Tianle Han ; Huaning Wang

ABSTRACT:

Although antipsychotics that act via monoaminergic neurotransmitter modulation have considerable therapeutic effect, they cannot completely relieve clinical symptoms in patients suffering from psychiatric disorders. This may be attributed to the limited range of neurotransmitters that are regulated by psychotropic drugs. Recent findings indicate the need for investigation of psychotropic medications that target less-studied neurotransmitters. Among these candidate neurotransmitters, lactate is developing from being a waste metabolite to a glial-neuronal signaling molecule in recent years. Previous studies have suggested that cerebral lactate levels change considerably in numerous psychiatric illnesses; animal experiments have also shown that the supply of exogenous lactate exerts an antidepressant effect. In this review, we have described how medications targeting newer neurotransmitters offer promise in psychiatric diseases; we have also summarized the advances in the use of lactate (and its corresponding signaling pathways) as a signaling molecule. In addition, we have described the alterations in brain lactate levels in depression, anxiety, bipolar disorder, and schizophrenia and have indicated the challenges that need to be overcome before brain lactate can be used as a therapeutic target in psychopharmacology.

2024-03-01·Photodermatology, photoimmunology & photomedicine

Sun pain and solar dysesthesia: A new challenge in clinical practice.

Review

作者: Piergiacomo Calzavara-Pinton ; Francesco Tonon ; Irene Calzavara-Pinton

BACKGROUND:

A few patients report intense pain and other unpleasant sensations, such as burning, dysesthesia and hyperalgesia, after even brief exposure to the sun and in the absence of any skin lesion. Sometimes they also develop systemic symptoms, such as mild fever, fatigue, faintness and fainting. As a result, these patients carefully avoid even short-term sun exposure with a consequent severe negative impact on their lives.

METHODS:

We have reviewed the clinical findings and the results of photobiological investigations of 10 patients who presented this clinical picture. Six of these patients were previously described by our group with the diagnosis of sun pain. We have reviewed the similarities with other previously described disorders such as solar dysesthesia and PUVA pain and have evaluated possible pathogenetic mechanisms.

RESULTS:

During phototesting our patients experienced intense pain in the exposed area and in the surrounding skin, without any visible lesion, even with very low sub-erythemal doses. At follow-up, five patients were diagnosed with fibromyalgia, three with a major depressive disorder, one with bipolar syndrome and one with a conversion disorder. The pathogenesis remains unclear, but the use of a psychopharmacological treatment with antidepressants improved both the neuropsychiatric symptoms and sensitivity to the sun in most subjects.

CONCLUSION:

For patients with pain and other severe symptoms in the absence of skin lesions and clinical and laboratory manifestations of known photodermatoses, a neuropsychiatric evaluation should be suggested.

891

项与躁郁症相关的新闻（医药）

2024-03-31

·BiG生物创新社

3月大事记：12项并购交易

作者｜小麦2024年3月，药企并购依然活跃，如诺和诺德11亿美元收购非编码RNA疗法公司Cardior、艾伯维2亿美元收购Landos Biopharma等（图1），本文细数3月进行的主要并购交易。图1. 3月并购事件3月28日，吉利德超6亿美元囊获创新肿瘤免疫疗法3月28日，吉利德和Xilio Therapeutics宣布达成一项总额可能超过6亿美元的独家许可协议，两家公司将共同开发和商业化Xilio的肿瘤激活白介素12(IL-12)蛋白XTX301，该在研药物目前处于临床1期阶段（图2）[1]。根据协议条款，Xilio授予吉利德开发和商业化XTX301的全球独家许可权。Xilio将收到4350万美元的预付款，并将有资格获得额外高达6.04亿美元的潜在开发、监管和销售等里程碑款项。3月26日，Immunome完成对Ayala Pharmaceuticals的收购3月26日，Immunome宣布完成对Ayala Pharmaceuticals的收购，获得了Ayala Pharmaceuticals的核心资产AL102和AL101等（图3）[2]。图3. Immunome完成对Ayala Pharmaceuticals的收购2024年2月6日，Immunome是宣布与Ayala Pharmaceuticals达成最终资产购买协议，根据协议条款，Immunome将在交易结束时向Ayala支付2000万美元现金和3000万美元 Immunome普通股，并将额外支付高达3750万美元的开发和商业里程碑付款。交易的完成取决于惯例条件，包括Ayala获得必要的股东批准。3月25日，诺和诺德11亿美元收购非编码RNA疗法公司Cardior2024年3月25日，诺和诺德将以高达10.25亿欧元（11亿美元）的价格收购Cardior Pharmaceuticals，包括预付款和如果实现某些开发和商业里程碑的额外付款（图4）[3]。Cardior 是发现和开发靶向 RNA 的疗法的领导者，这些疗法是预防、修复和逆转心脏疾病的手段。该公司的治疗方法以独特的非编码RNA为目标，作为解决心功能障碍根本原因的平台，旨在实现对患者的持久影响。此次收购的核心是Cardior的主要候选CDR132L，这是一种靶向miRNA132的基于寡核苷酸的抑制剂，目前正处于治疗心力衰竭的2期临床开发阶段。图4. 诺和诺德收购Cardior此次收购是诺和诺德在心血管疾病领域建立业务战略的重要一步。诺和诺德旨在通过内部和外部创新，建立一个有针对性、有影响力的治疗组合，以解决心血管疾病（全球最常见的死亡原因）中仍然存在的重大未满足需求。3月25日，艾伯维2亿美元收购Landos Biopharma2024年3月25日，艾伯维和Landos Biopharma宣布达成最终协议，根据该协议，艾伯维将以1.375亿美元（或每股20.42美元）的首付款以及可能为交易增加多达7500万美元的里程碑付款收购Landos，这是一家临床阶段的生物制药公司，专注于为自身免疫性疾病患者开发新型口服疗法（图5）[4]。图5. 艾伯维收购Landos BiopharmaLandos的主要研究资产是NX-13，这是一种首创的口服NLRX1激动剂（NOD样受体家族的成员），具有双重作用机制（MOA），有抗炎和促进上皮修复作用。NX-13的一项2期NEXUS临床试验目前正在美国和欧洲招募患者（NCT05785715 ClinicalTrials.gov）， NEXUS 是一项随机、多中心、双盲、安慰剂对照、多剂量、为期 12 周的诱导研究，评估了NX-13在80 名长期延长（LTE）期的临床疗效、安全性和药代动力学。3月20日，吉利德完成对CymaBay Therapeutics的收购2024年3月20日，吉利德宣布以约43亿美元的总股本价值完成对CymaBay Therapeutics的收购（图6）[5]。CymaBay的研究性主要候选产品用于治疗原发性胆汁性胆管炎（PBC），包括瘙痒症的seladelpar，是对吉利德现有肝脏产品组合的补充，并符合其为患者带来变革性药物的长期承诺。图6. 吉利德完成对CymaBay Therapeutics的收购3月20日，Lonza以12亿美元从罗氏手中购买美国生物制剂工厂2024年3月20日，作为制药、生物技术和营养保健品市场的全球制造合作伙伴，Lonza今天宣布已签署协议，以 12 亿美元的价格从罗氏手中收购位于美国加利福尼亚州瓦卡维尔的基因泰克大型生物制剂生产基地（图7）[6]。图7. Lonza购买罗氏的美国生物制剂工厂此次收购将显著提高Lonza的大规模生物制剂生产能力，以满足现有商业产品客户对商业哺乳动物合同生产的需求，以及目前Lonza商业化的分子。瓦卡维尔（美国）工厂目前的生物反应器总容量约为 330,000 升，使其成为世界上最大的生物制剂生产基地之一。根据协议，Genentech（美国）瓦卡维尔工厂的约750名员工将由Lonza提供工作。3月19日，阿斯利康24亿美元收购核药公司Fusion2024年3月19日，阿斯利康宣布以20亿美元（每股21美元现金）收购放射性药物公司Fusion Pharmaceuticals（图8）。每股 3 美元的未指定或有价值权利可能会使价值再增加 4 亿美元，此次收购总价值高达24亿美元[7]。Fusion是一家开发下一代放射性偶联物（RC）的临床阶段生物制药公司。此次收购标志着阿斯利康向前迈出了重要一步，通过用更有针对性的治疗取代化疗和放疗等传统方案，实现其改变癌症治疗和患者结果的雄心壮志。图8. 阿斯利康收购核药公司FusionFusion的主要候选药物是靶向前列腺特异性膜抗原（PSMA）药物FPI-2265，是一种针对转移性去势抵抗性前列腺癌（mCRPC）患者的潜在新疗法，目前正处于2期试验阶段。3月18日，BMS完成对Karuna的收购2024年3月18日，BMS宣布已成功完成对Karuna Therapeutics的收购。随着收购的完成，Karuna股票已停止在纳斯达克全球精选市场交易，Karuna现在是BMS的全资子公司（图9）[8]。图9. BMS完成对Karuna的收购在2023年12月22日，BMS宣布将以140亿美元收购Karuna，通过此次交易，BMS获得了KarXT（xanomeline-trospium），一种具有新颖作用机制和差异化疗效和安全性的抗精神病药，以及Karuna的早期和临床前产品线。KarXT是一款潜在的“first-in-class”用于治疗精神分裂症的药物，KarXT的新药上市申请（NDA）已于11月29日被FDA接受，申请的处方药用户付费方案（PDUFA）日期为2024年9月26日，如果获得批准，KarXT将代表几十年来第一种治疗精神分裂症的新药理学方法。KarXT也处于注册试验中，用于精神分裂症现有标准护理药物的辅助治疗和阿尔茨海默病患者精神病的治疗，并有可能扩展到其他适应症，包括双相I型障碍和阿尔茨海默病。3月18日，BiomX完成对Adaptive Phage Therapeutics的收购2024年3月18日，BiomX宣布已完成对Adaptive Phage Therapeutics的收购，Adaptive Phage是一家总部位于美国的私营临床阶段生物技术公司，率先开发基于噬菌体的疗法来对抗细菌感染，之前宣布获得了5000万美元融资（图10）[9]。图10. BiomX完成对Adaptive Phage Therapeutics的收购2024年3月6日，BiomX宣布已与Adaptive phage达成最终合并协议。在收购生效后，同时进行私募之前，BiomX的前股东将立即拥有BiomX和APT合并实体约55%的股份，而APT的前股东将拥有约45%的股份。BiomX 的核心产品包括BX004和BX211。BX004是一种固定的多噬菌体混合物，用于治疗由铜绿假单胞菌引起的慢性肺部感染的 CF 患者，铜绿假单胞菌是导致 CF 患者发病率和死亡率的主要原因。2023 年 11 月，BiomX 宣布了 1b/2a 期研究第 2 部分的积极顶线结果，其中 BX004 在预定义的肺功能下降。BX211是APT开发的一种个性化噬菌体治疗，用于治疗与金黄色葡萄球菌相关的DFO。个性化噬菌体治疗根据从每位患者身上活检和分离的金黄色葡萄球菌的特定菌株，从专有噬菌体库中选择特定的噬菌体。DFO 是一种骨骼细菌感染，通常由受感染的足部溃疡发展而来，是糖尿病患者截肢的主要原因。3月14日，阿斯利康10.5亿美元收购Amolyt Pharma 2024年3月14日，阿斯利康宣布已达成收购Amolyt Pharma的最终协议，Amolyt Pharma是一家临床阶段的生物技术公司，专注于开发罕见内分泌疾病的新疗法（图11）[10]。图11. 阿斯利康收购Amolyt Pharma根据协议条款，阿斯利康将以高达10.5亿美元的总对价收购Amolyt Pharma的所有流通股，无现金和无债务。这包括交易完成时的 8 亿美元预付款，以及 Amolyt Pharma 股东在达到特定监管里程碑后获得 2.5 亿美元额外或有付款的权利。此次收购将加强阿斯利康罕见病的后期管线，并扩大其骨代谢特许经营权，获得了Amolyt核心资产eneboparatide（AZP-3601），这是一种3期研究性治疗肽，具有新颖的作用机制，旨在满足甲状旁腺功能减退症的关键治疗目标。3月11日，Merck完成对Harpoon Therapeutics的收购2024年3月11日，Merck宣布完成对Harpoon Therapeutics的收购。Harpoon现在是默克公司的全资子公司，Harpoon的普通股将不再在纳斯达克股票市场公开交易或上市（图12）[11]。根据合并协议的条款，默克公司通过子公司收购了Harpoon的所有已发行股份。如前所述，该交易被核算为资产收购。默克公司对研发费用的非税收抵扣费用约为6.5亿美元。该交易对预期全年非GAAP每股收益的影响约为每股0.26美元，该影响已包含在默克于2024年2月1日发布的2024年全年财务展望中。图12. Merck完成对Harpoon Therapeutics的收购Harpoon的主要候选药物MK-6070（以前称为HPN328）是一种靶向δ样配体3（DLL3）的T细胞接合剂，DLL3是一种抑制性的典型Notch配体，在小细胞肺癌（SCLC）和神经内分泌肿瘤中高水平表达。MK-6070 的安全性、耐受性和药代动力学目前正在 1/2 期临床试验（NCT04471727）中作为单一疗法进行评估，用于治疗某些与 DLL3 表达相关的晚期癌症患者。该研究还在评估MK-6070与atezolizumab联合治疗某些SCLC患者。2022 年 3 月，美国食品和药物管理局（FDA）授予 MK-6070 孤儿药资格，用于治疗 SCLC。3月7日，强生完成对Ambrx Biopharma的收购2024年3月7日，强生宣布已成功完成对Ambrx Biopharma的收购，Ambrx是一家临床阶段的生物制药公司，拥有专有的合成生物学技术平台，用于设计和开发下一代抗体药物偶联物（ADC），通过全现金合并交易，总股本价值约为20亿美元，扣除估计收购现金后为19亿美元。正如 2024 年 1 月 8 日宣布的那样。该交易将作为企业合并进行会计处理（图13）[12]。图13. 强生完成对Ambrx Biopharma的收购主要参考文献 1. Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program2. Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala3.Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease4.AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases5.Gilead Sciences Announces Completion of Acquisition of CymaBay6.Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche7.AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer8.Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio9.BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing10.AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline11.Merck Completes Acquisition of Harpoon Therapeutics, Inc.12.Johnson & Johnson Completes Acquisition of Ambrx共建Biomedical创新生态圈！如何加入BiG会员？

并购临床2期寡核苷酸免疫疗法临床3期

2024-03-30

·生物谷

Nature | 精神分裂症患者和老年人的脑组织中存在一系列相似的基因活性变化

在一项新的研究中，来自美国布罗德研究所、哈佛医学院和麦克林医院的研究人员在精神分裂症患者和老年人的脑组织中发现了一系列惊人相似的基因活性变化。这些变化表明，精神分裂症患者和老年人经常出现的认知障碍有一个共同的生物学基础。相关研究结果发表在2024年3月21日的Nature期刊上，论文标题为“A concerted neuron–astrocyte program declines in ageing and schizophrenia”。具体而言，他们通过分析 191 人死后脑组织中 100 多万个细胞的基因表达，发现在精神分裂症患者和未患精神分裂症的老年人中，与健康人或年轻人相比，两种称为星形胶质细胞和神经元的脑细胞类型减少了支持神经元之间的突触的基因表达。他们还发现这两种细胞类型中的基因表达发生了紧密同步的变化：当神经元减少与突触有关的某些基因的表达时，星形胶质细胞也同样改变了支持突触的一组不同基因的表达。这些作者将这一系列协调变化称为“突触神经元和星形胶质细胞程序（Synaptic Neuron and Astrocyte Program, SNAP）”。即使是健康的年轻人，他们的神经元和星形胶质细胞中 SNAP 基因的表达也总是以协调的方式增加或减少。论文共同通讯作者、布罗德研究所成员Steve McCarroll说，“科学界通常关注的是每种细胞类型各自表达哪些基因。但是，来自许多人的脑组织，以及对这些数据的机器学习分析，帮助我们认识到了一个更大的系统。这些细胞类型不是作为独立的实体行动，而是有着非常密切的协调。这些关联的强度让我们叹为观止。”精神分裂症以导致幻觉和妄想而闻名，至少部分上可以通过药物进行治疗。然而，它也会导致令人衰弱的认知能力衰退，这种衰退没有有效的治疗方法，且在衰老过程中也很常见。这些研究结果表明，精神分裂症患者和老年人的认知变化可能涉及大脑中类似的细胞和分子变化。论文共同通讯作者、哈佛医学院副教授Sabina Berretta说，“为了检测精神分裂症和衰老过程中星形胶质细胞和神经元之间的协调性，我们需要研究大量个体的组织样本。我们感谢所有捐赠者，他们选择将自己的大脑捐献给研究，以帮助其他患有脑部疾病的人。”SNAP见解大脑之所以能发挥作用，在很大程度上是因为神经元在突触处与其他神经元相连接，它们在突触处相互传递信号。大脑会不断形成新的突触并修剪旧的突触。科学家们认为，新的突触有助于人类的大脑保持灵活，而之前的研究已表明，与精神分裂症有关的许多遗传因素都涉及有助于突触功能的基因。图片来自Nature, 2024, doi:10.1038/s41586-024-07109-5在这项新研究中，McCarroll、Berretta及其同事们利用单核 RNA 测序技术测量单个细胞中的基因表达，以更好地了解大脑是如何因人而异的。他们分析了来自94名精神分裂症患者和97名非精神分裂症患者的120万个细胞。他们发现，当神经元提高了编码部分突触的基因的表达时，星形胶质细胞则提高了一组与突触功能有关的独特基因的表达。这些基因组成了SNAP程序，其中包括许多以前发现的精神分裂症风险因素。他们的分析表明，神经元和星形胶质细胞都形成了精神分裂症的遗传易感性。论文第一作者、McCarroll实验室博士后研究员Emi Ling说，“科学界早就知道神经元和突触对精神分裂症的风险很重要，但通过以不同的方式提出问题——询问每种细胞类型动态调节哪些基因，我们发现星形胶质细胞也可能参与其中。”令这些作者惊讶的是，他们还发现即使在没有精神分裂症的人群中，SNAP也存在很大差异，这表明SNAP可能与健康人的认知差异有关。这种差异在很大程度上是由年龄造成的；SNAP在许多年龄较大的人中大幅下降，包括精神分裂症患者和非精神分裂症患者。McCarroll说，随着对SNAP有了更好的了解，他希望有可能找出对SNAP有积极影响的生活因素，并开发出有助于刺激SNAP的药物，以此来治疗精神分裂症患者中的认知障碍，或帮助人们在年老时保持认知灵活性。与此同时，McCarroll、Berretta和他们的团队正在努力了解这些变化是否存在于双相情感障碍和抑郁症等其他疾病中。他们还希望了解 SNAP 在其他大脑出现中的出现程度，以及 SNAP 如何影响学习和认知灵活性。参考资料：Emi Ling et al. A concerted neuron–astrocyte program declines in ageing and schizophrenia. Nature, 2024, doi:10.1038/s41586-024-07109-5.Schizophrenia and aging may share a common biological basis: Genetic changes in two types of brain cellshttps://medicalxpress.com/news/2024-03-schizophrenia-aging-common-biological-basis.html本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

基因疗法临床研究

2024-03-29

·PRNewswire

World Syndromic Multiplex Panels Market Analysis, Strategies, Trends and Forecasts, 2024-2028: A New Post Pandemic Growth Phase as New Entrants Jockey for Position in a New Diagnostic World

DUBLIN, March 29, 2024 /PRNewswire/ -- The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to ResearchAndMarkets.com's offering. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics. Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home? Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size for five years and even further with a later updated report with next years numbers. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What are Syndromic Multiplex Tests? 2.2 Syndromic Testing - the quiet revolution in diagnostics 2.2.1 Syndromic Testing - more than Panels. 2.3 Market Definition 2.4 Methodology 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 Infectious Disease 3.1 Infections - The Big Picture 3.2 The Pathogens 3.2.1 Bacteria 3.2.2 Fungi and Protozoa 3.2.3 Viruses 3.2.4 Prions 3.3 Symptoms and Syndromes 3.3.1 Bacterial or viral 3.3.2 Typical Viral Symptoms 3.3.3 Typical Bacterial Symptoms 3.4 Disease 3.5 Transmission 3.6 Infectious Disease Diagnostics 3.6.1 Microbial culture 3.6.2 Microscopy 3.6.3 Biochemical tests 3.6.4 PCR-based diagnostics 3.6.5 Metagenomic sequencing 3.7 Defining Infections 3.8 Syndromic Infection 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 The Clinical Laboratory Market Segments 4.2.1 Traditional Market Segmentation 4.2.2 Laboratory Focus and Segmentation 4.2.3 Segmenting the Syndromic Testing Market 4.3 Industry Structure 4.3.1 Hospital Testing Share 4.3.2 Economies of Scale 4.3.2.1 Hospital vs. Central Lab 4.3.3 Physician Office Lab's 4.3.4 Physician's and POCT 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Speed of Diagnosis. 5.1.2 Effect of Syndromic Testing on Costs. 5.1.3 Point of Care Advantage. 5.1.4 Accuracy and Diagnostic Risk. 5.1.5 Single Visits. 5.1.6 Improvement in Outcomes. 5.1.7 Impact of the Pandemic. 5.2 Factors Limiting Growth 5.2.1 Lower Prices. 5.2.2 Administration/reimbursement. 5.2.3 Infectious Disease is Declining But.. 5.2.4 Wellness Hurts. 5.2.5 Economic Growth improves Living Standards. 5.2.6 Impact of the Pandemic 5.3 Instrumentation, Automation and Diagnostic Trends 5.3.1 Traditional Automation and Centralization 5.3.2 The New Automation, Decentralization and Point of Care 5.3.3 Instruments Key to Market Share 5.3.4 Bioinformatics Plays a Role 5.3.5 PCR Takes Command 5.3.6 Next Generation Sequencing Fuels a Revolution 5.3.7 NGS Impact on Pricing 5.3.8 Whole Genome Sequencing, A Brave New World 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 5.3.10 Comparing Syndrome and Targeted Testing 5.3.11 The Multiplex Paradigm Shift 5.3.12 The Sepsis Testing Market - Bellwether for Syndromics 5.3.13 The Single Visit and AntiMicrobial Resistance 5.3.14 Syndromics drives POCT adoption. 6 Syndromic Testing Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 BioMerieux Submits Application for Respiratory, Sore Throat Panel 6.3 Sensible Diagnostics Nabs Award for Respiratory Panel 6.4 Aptitude Medical Systems to Develop At-Home STI Test 6.5 Multiplex Meningitis/Encephalitis Panel Market Expanding 6.6 Burst Dx to Deliver Lab-Accurate ELISA-in-a-Cartridge 6.7 OpGen Seeking Approval for UTI Panel 6.8 Altratech to Enter MDx, POC Space by Supplanting PCR 6.9 BIOFIRE Announces New SPOTFIRE System 6.10 Cambridge Nucleomics to Develop 'Nanobait' Tech 6.11 Takara Bio Developing Multiplex Panels 6.12 Rover Diagnostics Developing Optical Multiplex PCR 6.13 Nanopath Secures Funding to Develop POC Dx 6.14 Genetic Signatures Wins Public Health Wales Contract 6.15 Qiagen Looks to Long-Term Growth 6.16 LexaGene Gets Investment 6.17 Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval 6.18 BforCure to Adapt Rapid PCR Platform for Cancer 6.19 Accelerated Growth for Decentralized Testing 6.20 QuantuMDx Developing Syndromic Panels for European Launch 6.21 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel 6.22 QuantumDx Gets CE Mark for Rapid PoC PCR System 6.23 Bio-Rad Laboratories, Seegene Partner for MDx Development 6.24 Baebies to Expand Finder Platform 6.25 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio 6.26 Binx Health Targeting Clinics, DTC & OTC With STI Tests 6.27 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV 6.28 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic 6.29 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test 6.30 New Approach Involves Silicon-Based Test for Infectious Disease Screening 6.31 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test 6.32 Qiagen sees NeuMoDx as Growth Vehicle 6.33 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround 6.34 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests 6.35 BioMerieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU 6.36 Infectious Disease Testing Firm Curative Acquires KorvaLabs 6.37 ChromaCode Raises Additional $10M 6.38 COVID-19 Patients Need Syndromic Testing 6.39 GenMark Diagnostics - New Respiratory Panel due in June 6.40 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark 6.41 Exact Diagnostics launches respiratory panel control 6.42 bioMerieux submits enhanced BIOFIRE BCID2 Panel to FDA 7 Profiles of Key Syndromic Testing Companies 7.1 Abacus Diagnostica 7.2 Abbott Laboratories 7.3 Accelerate Diagnostics 7.4 Ador Diagnostics 7.5 ADT Biotech 7.6 Akonni Biosystems 7.7 Alveo Technologies 7.8 Antelope Dx 7.9 Applied BioCode 7.10 Aureum Diagnostics 7.11 Aus Diagnostics 7.12 Baebies 7.13 Beckman Coulter Diagnostics 7.14 Becton, Dickinson and Company 7.15 Binx Health 7.16 Biocartis 7.17 BioFire Diagnostics (bioMerieux) 7.18 bioMerieux Diagnostics 7.19 Bio-Rad Laboratories, Inc 7.20 Bosch Healthcare Solutions GmbH 7.21 Cepheid (Danaher) 7.22 Credo Diagnostics Biomedical 7.23 Cue Health 7.24 Curetis N.V./Curetis GmbH 7.25 Detect 7.26 Diagenode Diagnostics 7.27 Diasorin S.p.A. 7.28 Domus Diagnostics 7.29 Enzo Biochem 7.30 Eurofins Scientific 7.31 Fluxergy 7.32 Fusion Genomics. 7.33 Genetic Signatures 7.34 GenMark Dx (Roche) 7.35 Grip Molecular Technologies 7.36 Hibergene Diagnostics 7.37 Hologic 7.38 Immunexpress 7.39 Inflammatix 7.40 Invetech 7.41 Janssen Diagnostics 7.42 Karius 7.43 Lexagene 7.44 LightDeck Diagnostics 7.45 Lucira Health 7.46 Luminex Corp (DiaSorin) 7.47 Maxim Biomedical 7.48 Meridian Bioscience 7.49 Mesa Biotech (Thermo Fisher) 7.50 MicroGem 7.51 Millipore Sigma 7.52 Minute Molecular 7.53 Mobidiag (Hologic) 7.54 Molbio Diagnostics 7.55 Nanomix 7.56 Novel Microdevices 7.57 OnsiteGene 7.58 Operon 7.59 Oxford Nanopore Technologies 7.60 Panagene 7.61 Perkin Elmer 7.62 Primerdesign (Novacyt) 7.63 Prominex 7.64 Proof Diagnostics 7.65 Qiagen 7.66 QuantuMDx 7.67 QuidelOrtho 7.68 Roche Molecular Diagnostics 7.69 Saw Diagnostics 7.70 Scope Fluidics 7.71 Seegene 7.72 Siemens Healthineers 7.73 Sona Nanotech 7.74 SpeeDx 7.75 T2 Biosystems 7.76 Talis Biomedical 7.77 Thermo Fisher Scientific Inc. 7.78 Vela Diagnostics 7.79 Veramarx 7.80 Visby Medical 7.81 XCR Diagnostics 8 The Global Market for Syndromic Multiplex Diagnostics 8.1 Global Market Overview by Country 8.2 Global Market by Syndrome - Overview 8.3 Global Market by Place - Overview 8.4 Global Market by Product - Overview 9 Global Syndromic Multiplex Markets - By Syndrome 9.1 Respiratory 9.2 Gastrointestinal 9.3 Blood 9.4 Meningitis/Encephalitis 9.5 Sexually Transmitted Disease 9.6 Other Syndrome 10 Global MDx Infectious Disease Markets - by Place 10.1 Hospital Lab 10.2 Outpatient Lab 10.3 Point of Care 10.4 Other Place 11 Global MDx Infectious Disease Markets - by Product 11.1 Instruments 11.2 Cartridges 11.3 Reagents 11.4 Other Product 12 Appendices 12.1 United States Medicare System: Clinical Laboratory Fees Schedule 12.2 The Most Used IVD Assays 12.3 The Highest Grossing Assays For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

诊断试剂